New Targets for PET Molecular Imaging of Prostate Cancer

Area of Science:

• Oncology
• Radiochemistry
• Molecular Imaging

Background:

• Prostate cancer (PCa) is a common malignancy with variable behavior.
• Conventional imaging (CT, MRI, bone scans) has limited accuracy for detecting early or recurrent PCa, especially with low PSA levels.
• This diagnostic gap necessitates advanced imaging techniques.

Purpose of the Study:

• To review current and emerging PET molecular imaging probes for prostate cancer.
• To highlight the advancements in PET tracer technology for PCa detection and staging.
• To discuss the potential of novel probes in overcoming limitations of conventional imaging.

Main Methods:

• Review of recent literature on PET radiotracers for prostate cancer.
• Discussion of established and novel PET agents including choline, 18F-fluciclovine, bombesin, and PSMA ligands.
• Analysis of the performance and sensitivity of various PET probes in PCa detection.

Main Results:

• Multiple PET probes demonstrate significant potential in identifying PCa recurrence and disease extent.
• Prostate-specific membrane antigen (PSMA)-PET agents exhibit high sensitivity and are expected to become widely available.
• Emerging tracers like bombesin-based radiotracers and RM2 show promise as alternatives.

Conclusions:

• PET molecular imaging is rapidly evolving, offering superior detection capabilities for prostate cancer.
• PSMA-PET agents are leading the way in sensitivity and clinical utility for PCa staging and recurrence.
• Future research and development in PET tracers will further enhance diagnostic accuracy in prostate cancer management.